Intake of probiotic bacteria may improve or preserve insulin sensitivity. Fetuin-A and sestrin 3 have emerged as promising candidate biomarkers for crucial roles in insulin signaling pathway. Therefore, the effect of oral supplementation with the probiotic bacterium Lactobacillus delbrueckii subsp. lactis PTCC1057 on proteins involved in insulin signaling pathway was investigated in normal and streptozotocin (STZ)-induced diabetic mice. The 6-8-week-old female mice were divided into a non-diabetic control, diabetic control, and diabetic experimental and non-diabetic experimental groups (5 mice each group). Diabetic and non-diabetic experimental groups treated with 3 × 107 CFU mL-1 L. delbrueckii subsp. lactis PTCC1057 by gavage feeding approach daily for 28 days. Serum glucose, fetuin-A, and sestrin 3 levels were measured by standard methods. The result showed that oral administration of L. delbrueckii significantly decreased serum glucose in comparison to diabetic control group (P = 0.01). Serum fetuin-A level was higher in diabetic control group than non-diabetic group and oral administration of L. delbrueckii subsp. lactis PTCC1057 significantly decreased fetuin-A level in diabetic experimental group in comparison with non-diabetic groups (P = 0.001). Sestrin 3 level significantly was lower in diabetic control group than non-diabetic control group (P = 0.03) and it significantly increased in diabetic experimental group in comparison with diabetic control group after intervention of L. delbrueckii subsp. lactis PTCC1057 (P = 0.02). The results show that feeding the STZ-induced diabetic mice with L. delbrueckii subsp. lactis PTCC1057 terminated to decrease in fasting blood glucose and fetuin-A level and increase in serum sestrin 3 level. Therefore, the L. delbrueckii subsp. lactis PTCC1057 can be considered as excellent candidate for future studies on diabetes mellitus.

中文翻译：

---

德氏乳杆菌亚种的作用。lactis PTCC1057 对链脲佐菌素诱导的糖尿病小鼠血清葡萄糖、胎球蛋白-A 和 Sestrin 3 水平的影响。

摄入益生菌可以改善或保持胰岛素敏感性。Fetuin-A 和 sestrin 3 已成为在胰岛素信号通路中发挥关键作用的有希望的候选生物标志物。因此，口服补充益生菌德氏乳杆菌亚种的效果。在正常和链脲佐菌素 (STZ) 诱导的糖尿病小鼠中研究了 lactis PTCC1057 对参与胰岛素信号通路的蛋白质的影响。将6-8周龄雌性小鼠分为非糖尿病对照组、糖尿病对照组、糖尿病实验组和非糖尿病实验组(每组5只小鼠)。用 3 × 107 CFU mL-1 L. delbrueckii subsp. 治疗的糖尿病和非糖尿病实验组。乳酸菌PTCC1057通过每天灌胃喂养的方法持续28天。通过标准方法测量血清葡萄糖、胎球蛋白-A 和 sestrin 3 水平。结果表明，与糖尿病对照组相比，口服德氏乳杆菌显着降低了血糖（P = 0.01）。糖尿病对照组的血清胎球蛋白-A 水平高于非糖尿病组和口服德氏乳杆菌亚种。与非糖尿病组相比，乳酸菌PTCC1057显着降低了糖尿病实验组的胎球蛋白-A水平（P = 0.001）。糖尿病对照组与非糖尿病对照组相比，Sestrin 3 水平显着降低（P = 0.03），在德氏乳杆菌干预后，糖尿病实验组与糖尿病对照组相比显着升高。乳酸菌PTCC1057 (P = 0.02)。结果表明，用德氏乳杆菌亚种喂养 STZ 诱导的糖尿病小鼠。乳酸菌PTCC1057终止空腹血糖和胎球蛋白A水平降低，血清sestrin 3水平升高。因此，德氏乳杆菌亚种。lactis PTCC1057 可以被认为是未来糖尿病研究的优秀候选者。